A multi-centred open trial of “Dr Michaels®” (also branded as Soratinex®) topical product family in psoriasis.

A multi-centred open trial of “Dr Michaels®” (also branded as Soratinex®) topical product family in psoriasis. J Biol Regul Homeost Agents. 2016 Apr-Jun;30(2 Suppl 3):1-7 Authors: Wollina U, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Tirant M, Novotny F, Roccia MG, Maximov GK, França K, Lotti T Abstract Psoriasis is a chronic, recurring skin disease affecting 2-4% of the population. Genetic predisposition and precipitating factors play a role in its etiology. The disease can occur in any age or gender group. The most frequently affected areas of the body include scalp, extensor surfaces of the extremities, skin folds and nails. While a number of therapies exist for the treatment of psoriasis with a total resolution of the skin, achieving remission in a high percentage of sufferers, a treatment that results in the maintenance of remission and is free of side effects is still a desirable goal. The aim of the study was to investigate the efficacy and tolerability of Dr Michaels® (Soratinex®) topical product family in psoriasis, in terms of decreasing parakeratosis, inflammation, infiltration and involved area. Seven-hundred-and-twenty-two subjects, mean age 42.3 years (range: 18-68 years) with mild to moderately severe psoriasis, with no other current anti-psoriatic therapy, consisting of 382 males and 340 females, above 18 years of age were included and the observations were subjected to statistical ana...
Source: Journal of Biological Regulators and Homeostatic Agents - Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research